Tracking the History of Tucatinib for Breast Cancer Treatment at SABCS
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
Category: Meetings
Throughout the years, SABCS has shown how tucatinib has progressed into a potential frontline therapy for HER2-positive breast cancer.
New insights into the neurologic and physiologic impact of chronic stress on ovarian cancer were presented at two recent...
Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.
Shawn Lee, MD, PhD, an AACR-St. Baldrick’s Foundation Grantee, is working to personalize therapies for children with acute lymphoblastic...
Laura M. Heiser, PhD, and Mara H. Sherman, PhD share insights on cancer evolution as they preview an upcoming...
Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Since 1993, the American Association for Cancer Research (AACR) has invested more than $542 million in grants to sustain...
Frontiers in Cancer Science 2025 cochairs, Soo Chin Lee and Reshma Taneja, preview this international cancer conference in Singapore.
The AACR Conference on the Science of Cancer Health Disparities explored the field's evolving landscape, including funding and and...
Frank McCormick, PhD, FAACR, reflected on a career chasing the notorious RAS oncogene that earned him the inaugural Stephenson...